The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma
Study Details
Study Description
Brief Summary
This study is being conducted to explore the efficacy and safety of neoadjuvant toripalimab combined with temozolomide in resectable stage III melanoma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
This trial is a prospective, single-center, single-arm clinical research. Unlike seen in Caucasians, checkpoint inhibitors have not obtained satisfactory results in Chinese patients. Exploring the curative effects of combination therapies in melanoma and their potential synergetic mechanism will improve the prognosis of patients. Recent retrospective data in our center showed that the objective response rate (ORR) of immunotherapy plus chemotherapy in advanced melanoma reached 40%, which was higher than immunotherapy (12.5%) and chemotherapy (4%) alone as front-line therapies. This study is aiming to evaluate the efficacy and safety of toripalimab combined with temozolomide in patients with resectable stage III melanoma. The safety and efficacy of this study will be assessed through ORR, DCR, PFS, OS, and adverse effects as graded by CTCAE 5.0.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Toripalimab Combined With Temozolomide Toripalimab Combined With Temozolomide |
Drug: Toripalimab combined with Temozolomide
Toripalimab combined with Temozolomide
|
Outcome Measures
Primary Outcome Measures
- Pathologic response rate (pRR) [Within one week after operation]
After 2 cycles of neoadjuvant toripalimab combined with temozolomide, patients receive radical surgery.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Has resectable stage IIIB-IIID melanoma of acral and cutaneous type, according to American Joint Committee on Cancer (AJCC) staging system version 8. At least one measurable lesion conforming to RECIST 1.1 criteria.
-
No previously received systematic therapy of anti-PD-1 plus temozolomide. For patients with relapsed melanoma, previous therapy of anti-PD-1 plus temozolomide has been stopped for more than 6 months is acceptable.
For patients with disease progressed after receiving immune checkpoint inhibitors only, time from the last treating day is ≥ 4 weeks.
-
The toxicity of prior treatment has recovered to ≤1 grade according to CTCAE 5.0.
-
ECOG score 0-1.
-
The expected survival time is ≥ 12 weeks.
-
Adequate organ and bone marrow function.
-
Female subjects of childbearing age must undergo a serum pregnancy test within 7 days before the commencement of the study and the results are negative, and are willing to use a medically approved high potency contraceptive method during the study period and within 3 months after the last administration of the study drug; For male subjects whose partner is a female of childbearing age, they should be surgically sterilized or agree to use an effective method of contraception during the study period and for 3 months after administration of the last study.
-
Willing to consent and signed the informed consent, and able comply with the planned visit, research treatment, laboratory examination and other test procedures.
Exclusion Criteria:
-
Has mucosal melanoma or choroidal melanoma.
-
The first study drug treatment was less than 4 weeks from the last systematic antitumor therapy or 5 half-lives from the last targeted therapy; less than 4 weeks from major surgery; less than7 days from immunosuppressive drug; less than 3 weeks from immunomodulatory; less than 4 weeks from live attenuated vaccine.
-
Systemic antibiotic use for 7 days within 4 weeks prior to initial administration, or unexplained fever during screening/prior to initial administration.
-
With active autoimmune disease or a history of autoimmune disease.
-
With history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
-
With immunodeficiency, eg HIV, HBV, HCV.
-
Have a clear history of serious and uncontrolled other disease or mental disorders.
-
Has a bleeding tendency or abnormal clotting function.
-
Known to be allergic to the active ingredients or excipients in this study.
-
Other situations that the researcher considers inappropriate to participate in the research.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Fudan University Shanghai Cancer Center | Shanghai | China |
Sponsors and Collaborators
- Yong Chen
Investigators
- Principal Investigator: Yong Chen, MD, Fudan University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FU-Name-T004